For the millions living with or at risk of ALS and frontotemporal dementia, understanding why TDP-43 misfolds and aggregates inside neurons has been a central unsolved puzzle. New atomic-level evidence now reveals that a specific chemical modification — oxidation of methionine residues — fundamentally rewires how TDP-43's disordered C-terminal domain self-organizes into liquid-like condensates, offering a mechanistic bridge between oxidative stress and neurodegeneration.
Using an integrated approach combining residue-resolved NMR spectroscopy with all-atom molecular dynamics simulations, researchers mapped how methionine oxidation reshapes the interaction networks governing TDP-43 condensate formation. The modification was found to alter both the helical assembly regions of the C-terminal domain and the transient contacts within its intrinsically disordered segments. These dual perturbations destabilize the normally reversible phase-separated state that TDP-43 occupies in healthy cells, providing a plausible molecular mechanism by which oxidative damage could tip condensates toward pathological solid aggregates characteristic of ALS pathology.
This work lands at an important intersection in neurodegeneration research. TDP-43 proteinopathy is now recognized as a hallmark of roughly 97% of ALS cases and a significant fraction of frontotemporal dementia, yet the triggers converting dynamic condensates into toxic aggregates have remained elusive. Oxidative stress is chronically elevated in aging neurons and in ALS patient tissue, making methionine — one of the most oxidation-prone amino acids — a structurally plausible vulnerability point. The residue-by-residue resolution achieved here surpasses most prior condensate studies, which typically rely on coarser biochemical assays. Key limitations include the in vitro nature of the system; whether oxidation events at these specific methionines occur in vivo at pathologically relevant rates, and whether they precede or follow aggregate seeding, remains to be established. Nonetheless, this mechanistic precision makes the finding incrementally significant and positions specific methionine sites as potential therapeutic targets for small molecules or antioxidant strategies aimed at preserving TDP-43 condensate reversibility.